Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Buchdunger

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|November 14, 1997
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidinesP Traxler, G Bold, J Frei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinomaC C Solorzano, C H Baker, R Tsan, et al.
Journal of Medicinal Chemistry|April 1, 1994
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinaseU Trinks, E Buchdunger, P Furet, et al.
Cancer Research|October 4, 2000
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine classT Kilic, J A Alberta, P R Zdunek, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1994
4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activityE Buchdunger, U Trinks, H Mett, et al.
Cancer Research|August 2, 2001
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosisT Sjöblom, A Shimizu, K P O'Brien, et al.
Cancer Research|August 14, 1999
The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BBA Shimizu, K P O'Brien, T Sjöblom, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 1998
RetractionsE Buchdunger, U Trinks, H Mett, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2005
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 gliomaT O'Reilly, M Wartmann, S-M Maira, et al.
Cancer Research|June 13, 2000
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinomaC J Bruns, C C Solorzano, M T Harbison, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|November 14, 1997
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidinesP Traxler, G Bold, J Frei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinomaC C Solorzano, C H Baker, R Tsan, et al.
Journal of Medicinal Chemistry|April 1, 1994
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinaseU Trinks, E Buchdunger, P Furet, et al.
Cancer Research|October 4, 2000
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine classT Kilic, J A Alberta, P R Zdunek, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1994
4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activityE Buchdunger, U Trinks, H Mett, et al.
Cancer Research|August 2, 2001
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosisT Sjöblom, A Shimizu, K P O'Brien, et al.
Cancer Research|August 14, 1999
The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BBA Shimizu, K P O'Brien, T Sjöblom, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 1998
RetractionsE Buchdunger, U Trinks, H Mett, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2005
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 gliomaT O'Reilly, M Wartmann, S-M Maira, et al.
Cancer Research|June 13, 2000
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinomaC J Bruns, C C Solorzano, M T Harbison, et al.
Pageof 5